tirzepatide 15 mg MOUNJARO / 0.5 ML ( ) FOR SUBCUTANEOUS INJECTION 4 VIALS Tirzepatide (4 x 15mg Vial)

When administered, it stimulates insulin secretion in response to food intake, helping to regulate blood sugar levels

Some people report mild nausea or a slight change in appetite, but these reports are rare at doses this low

This means that five days after injection, roughly half the medication remains active in your bloodstream

The gastrointestinal side effects are not necessarily life-threatening, but they can significantly reduce quality of life and make tirzepatide harder to tolerate during dose escalation

Iron supplements should be separated from thyroid medications, certain antibiotics, and calcium by at least 2-4 hours

Additionally, semaglutide should not be used concurrently with other GLP-1 receptor agonists